title: The hidden risk: Incorporating inflammation and HIV serostatus into coronary artery disease screening.
abstract: CAD is a well-established comorbidity associated with HIV infection. This association is in large part due to ongoing inflammation propagated by viremia and dysregulation of the immune system. Despite this knowledge, evidence to guide clinical management and screening for CAD among HIV-infected patients is lacking. The following editorial discusses recent evidence that HIV-infected patients with abnormal cardiovascular stress testing are more likely to undergo subsequent percutaneous coronary intervention. Importantly, the cardiovascular consequences of HIV infection and potential clinical implications are discussed.
authors.affiliation: Division of Cardiovascular Disease, University of Alabama at Birmingham, School of Medicine, Tinsley Harrison Tower, 1900 University Boulevard, Suite 311, Birmingham, AL 35233, USA. gpayne@uabmc.edu.
authors.forename: Gregory A
authors.initials: GA
authors.lastname: Payne
authors.affiliation: Division of Infectious Diseases, University of Alabama at Birmingham, Birmingham, AL, USA.
authors.forename: Edgar Turner
authors.initials: ET
authors.lastname: Overton
mesh_terms: D003324:Coronary Artery Disease; D005080:Exercise Test; D015658:HIV Infections; D006801:Humans; D007249:Inflammation; D062645:Percutaneous Coronary Intervention; D012307:Risk Factors
keywords: Human immunodeficiency virus; coronary artery disease; exercise: stress testing; inflammation; pharmacologic stress